KLSE (MYR): SUNZEN (0148)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
0.315
Today's Change
0.00 (0.00%)
Day's Change
0.00 - 0.00
Trading Volume
0
Market Cap
253 Million
NOSH
804 Million
Latest Quarter
30-Jun-2024 [#0]
Announcement Date
29-Aug-2024
Next Quarter
30-Sep-2024
Est. Ann. Date
29-Nov-2024
Est. Ann. Due Date
29-Nov-2024
QoQ | YoY
-79.55% | -56.24%
Revenue | NP to SH
99,889.000 | 7,177.000
RPS | P/RPS
12.42 Cent | 2.54
EPS | P/E | EY
0.89 Cent | 35.30 | 2.83%
DPS | DY | Payout %
0.00 Cent | 0.00% | 0.00%
NAPS | P/NAPS
0.18 | 1.79
QoQ | YoY
-6.73% | 75.61%
NP Margin | ROE
8.16% | 5.08%
F.Y. | Ann. Date
30-Jun-2024 | 29-Aug-2024
Latest Audited Result
30-Jun-2024
Announcement Date
30-Oct-2024
Next Audited Result
30-Jun-2025
Est. Ann. Date
30-Oct-2025
Est. Ann. Due Date
27-Dec-2025
Revenue | NP to SH
142,699.000 | 9,172.000
RPS | P/RPS
17.74 Cent | 1.78
EPS | P/E | EY
1.14 Cent | 27.63 | 3.62%
DPS | DY | Payout %
0.00 Cent | 0.00% | 0.00%
NAPS | P/NAPS
0.18 | 1.79
YoY
null%
NP Margin | ROE
7.31% | 6.50%
F.Y. | Ann. Date
30-Jun-2024 | 29-Aug-2024
Revenue | NP to SH
142,699.000 | 9,172.000
RPS | P/RPS
17.74 Cent | 1.78
EPS | P/E | EY
1.14 Cent | 27.63 | 3.62%
DPS | DY | Payout %
-
NAPS | P/NAPS
-
QoQ | YoY
22.03% | 129.87%
NP Margin | ROE
7.31% | 6.50%
F.Y. | Ann. Date
30-Jun-2024 | 29-Aug-2024
Trailing 4 Quarters | Trailing 8 Quarters | |||
---|---|---|---|---|
Available Quarters | 4 Quarters | 8 Quarters | ||
Continuous Quarters Of Revenue Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
Total Positive Profit Years | 4 / 4 | 100.00% | 8 / 8 | 100.00% |
Continuous Quarters Of Positive Profit | 4 / 4 | 100.00% | 8 / 8 | 100.00% |
Continuous Quarters Of Profit Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
Continuous Quarters Of Adjusted EPS Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
Total Dividend Years | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
Continuous Quarters Of Dividend | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
Continuous Quarters Of Dividend Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
Continuous Quarters Of Adjusted Dps Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
Average ROE | 1.39% | 1.11% | ||
Average Net Profit Margin | 7.69% | 6.58% |
Last 5 Financial Years | Last 10 Financial Years | |||
---|---|---|---|---|
Available Years | 5 Years | 10 Years | ||
Continuous Quarters Of Revenue Growth | 1 / 5 | 20.00% | 1 / 10 | 10.00% |
Total Positive Profit Years | 3 / 5 | 60.00% | 4 / 10 | 40.00% |
Continuous Quarters Of Positive Profit | 1 / 5 | 20.00% | 1 / 10 | 10.00% |
Continuous Quarters Of Profit Growth | 1 / 5 | 20.00% | 1 / 10 | 10.00% |
Continuous Quarters Of Adjusted EPS Growth | 1 / 5 | 20.00% | 1 / 10 | 10.00% |
Total Dividend Years | 0 / 5 | 0.00% | 1 / 10 | 10.00% |
Continuous Quarters Of Dividend | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
Continuous Quarters Of Dividend Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
Continuous Quarters Of Adjusted Dps Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
Average ROE | -0.90% | -2.81% | ||
Average Net Profit Margin | -0.29% | -1.18% |
T4Q | Annualized | Annual (Unaudited) | Last 10 FY Average | Last 5 FY Average | |
---|---|---|---|---|---|
Revenue | 99,889 | 142,699 | 142,699 | 132,845 | 82,495 |
NP to SH | 7,177 | 9,172 | 9,172 | -2,105 | 55 |
Dividend | 0 | 0 | 0 | 144 | 0 |
Adjusted EPS | 0.89 | 1.14 | 1.14 | -0.29 | 0.01 |
Adjusted DPS | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 |
NP to SH = Net Profit Attributable to Shareholder, EPS = Earning Per Share, DPS = Dividend Per Share
All figures in '000 unless specified.
EPS & DPS's figures in Cent.
LQ QoQ | LQ YoY | CQ YoY | LQ vs Average of T4Q | LQ vs Average of T8Q | |
---|---|---|---|---|---|
Revenue | -13.97% | 4.23% | 233.33% | -17.46% | -10.21% |
NP to Owner | -79.55% | -56.24% | 359.75% | -77.54% | -71.38% |
Dividend | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Adjusted EPS | -79.55% | -56.24% | 359.75% | -77.54% | -71.38% |
Adjusted DPS | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LQ = Latest Quarter, CQ = Cumulative Quarter, T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, QoQ = Quarter on Quarter, YoY = Year on Year
T4Q vs LFY | T4Q vs AL5FY | T4Q vs AL10FY | AQR vs LFY | AQR vs AL5FY | AQR vs AL10FY | LFY YoY | LFY vs AL5FY | LFY vs AL10FY | |
---|---|---|---|---|---|---|---|---|---|
Revenue | -30.00% | 21.08% | -24.81% | 0.00% | 72.98% | 7.42% | 0.00% | 72.98% | 7.42% |
NP to Owner | -21.75% | 12,949.09% | 440.80% | 0.00% | 16,576.36% | 535.54% | 0.00% | 16,576.36% | 535.54% |
Dividend | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Adjusted EPS | -21.75% | 12,949.04% | 440.80% | 0.00% | 16,576.29% | 535.54% | 0.00% | 16,576.29% | 535.54% |
Adjusted DPS | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, AL5FY = Average of Last 5 Financial Years, AL10FY = Average of Last 10 Financial Years, LFY = Latest Financial Year AQR = Annualized Quarter Result, YoY = Year on Year
caught some at 0.31... cheap & nice to hold... if this week can climb back like you say then nice lor..
2024-08-06 16:01
next qr should see some improvement with the positive growth of biotech industry
2024-08-07 16:20
0.31-0.32 is a steady & cheap entry price now, Sunzen entering the healthcare sector will push the price further up
2024-08-08 15:07
Strong growth every quarter, Sunzen future prospect is really bright with new acquisition
2024-08-09 16:10
Next quarter's revenue and net profit will both increase quarter-on-quarter and year-on-year, I believe
2024-08-12 20:08
Sunzen has decreased current liabilities to 6.3% of total assets over this period. Good sign
2024-08-13 16:15
I just watched it. Must say the new management seems to be doing the right thing compare to the previous one. At least now SUNZEN is no longer losing money but making profit
1 month ago
Hopes the Xmegami lenglui will buy in sunzen also since their earning so high every month
1 month ago
Watched the technical analysis here https://youtu.be/9V0_mkxG1sw?si=M-l0iuIJeU4w9q5Q
1 month ago
Dow Jones
Dow Jones Industrial Average
42,011.59
-184.93
0.43%
Nasdaq
NASDAQ Composite
17,918.47
-6.64
0.03%
1 month ago
Share price still steady after that, biggie0000. We wait for the next rally to come
2 weeks ago
As consumers pay more and more attention to preventive health care and natural remedies, Sunzen's traditional Chinese medicine and human health supplement products have huge growth potential
2 weeks ago
Nice grab, gloveshapiro. If the QR is good as expected, it probably will break 35 cents
2 weeks ago
Sunzen Biotech eyes bigger share of China bird’s nest market. Sunzen subsidiary Ecolite Biotech Manufacturing Sdn Bhd has received approval from China’s customs authority in October last year to export its bottled bird’s nest to the country up to 2028.
1 week ago
The demand for edible bird’s nest products is indeed strong in China, Hong Kong, and other parts of Southeast Asia. The Chinese market, in particular, is one of the largest consumers of bird’s nests, driven by a cultural preference for traditional health products and rising disposable incomes
1 week ago
Sunzen's loan financing business is expected to continue to grow given the increasing trend in the number of applications and approvals, mainly due to our ability to provide fast and efficient services and structure more flexible loan packages to meet the needs of the SME market.
3 days ago
Acquisition of Eye Nation Medical is expected to contribute positively to the future financial performance of the Sunzen group, enhancing the group’s revenue and profitability, as it is secured by a profit guarantee of an audited profit after tax of RM2.60 million over the next two financial years
1 day ago
Then SUNZEN will be able to achieve over RM1 million of net profit in the next quarter 😀
8 hours ago
Wixson
Great, SUNZEN still managed to stay above 30 cents today 👏
2024-08-05 19:43